All In Biotech

Drug Trial Radar · NCT05576675

Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal Surgery

Last checked: Nov 19, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,342 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,342

Actual

Start

May 1, 2018

Primary completion

Mar 31, 2022

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Objective To evaluate the effect of patient-controlled intravenous analgesia combined with different opioid receptors for gastrointestinal surgery. Methods A total of 4342 patients who underwent gastrointestinal postoperative analgesia in the first affiliated Hospital of Air Force military Medical University from May 2018 to March 2022 were collected retrospectively. The patient-controlled intravenous analgesia regimen in this study was composed of different opioid receptor drugs:sufentanil combined with nalbuphine group (SN group) and Hydromorphone combined with nalbuphine group (HN group) and single opioid receptor group: sufentanil group (S group). SN group ,HN group and S group were treated with sufentanil 100 μ g + nalbuphine 40 mg, hydromorphone 10 mg+ nalbuphine 40 mg, sufentanil 200 μ g, diluted to 100 ml, background dose 1 ml/h, PCA dose 0.5 ml, locking time 10 min. The demographic data of the three groups were collected, the number of patients with insufficient static and dynamic analgesia (VAS ≥ 4) at 24 and 48 hours after operation, the adverse reactions at 24 and 48 hours after operation, the first exhaust time and the first ambulation time were collected, evaluate the analgesic effect of combination of different opioid receptor drugs and single opioid receptor drugs in PCIA after gastrointestinal surgery.

Conditions

  • Gastrointestinal Surgery

Interventions

  • sufentanil + nalbuphineDrug

    sufentanil 100 μ g + nalbuphine 40 mg

  • SufentanilDrug

    sufentanil 200 μ g

  • hydromorphone + nalbuphineDrug

    hydromorphone 10 mg+ nalbuphine 40 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the incidence of insufficient static and dynamic analgesia dynamic analgesiaTime frame: 24 hours after operation
  2. the incidence of insufficient static and dynamic analgesia dynamic analgesiaTime frame: 48 hours after operation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • YANLI

    XIan, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.